Merck
CN
All Photos(1)

Documents

Y0000558

Fluconazole for peak identification

European Pharmacopoeia (EP) Reference Standard

Sign Into View Organizational & Contract Pricing
All Photos(1)
Synonym(s):
Fluconazole, 2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol
Empirical Formula (Hill Notation):
C13H12F2N6O
CAS Number:
86386-73-4
Molecular Weight:
306.27
MDL number:
MFCD00274549
PubChem Substance ID:
329831020
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

fluconazole

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

FC1=CC(F)=C(C(CN2N=CN=C2)(O)CN3N=CN=C3)C=C1

InChI

1S/C13H12F2N6O/c14-10-1-2-11(12(15)3-10)13(22,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9,22H,4-5H2

InChI key

RFHAOTPXVQNOHP-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Fluconazole for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Fluconazole is an antifungal agent. It is highly selective inhibitor of fungal cytochrome P-450 sterol C-14 α-demethyllation. Fluconazole is a potent inhibitor of CYP2C9. Fluconazole interferes with fungal ergosterol synthesis and downregulates the metallothionein gene.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

PHR1160

Fluconazole, Pharmaceutical Secondary Standard; Certified Reference Material

1271700

Fluconazole, United States Pharmacopeia (USP) Reference Standard

Y0000557

Fluconazole, European Pharmacopoeia (EP) Reference Standard

Y0000574

Fluconazole impurity C, European Pharmacopoeia (EP) Reference Standard

Y0000573

Fluconazole impurity B, European Pharmacopoeia (EP) Reference Standard

1271733

Fluconazole Related Compound C, United States Pharmacopeia (USP) Reference Standard

1271722

Fluconazole Related Compound B, United States Pharmacopeia (USP) Reference Standard

1271711

Fluconazole Related Compound A, United States Pharmacopeia (USP) Reference Standard

PHR1651

Fluconazole Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1826

Fluconazole Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1862

Fluconazole Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2037

Fluconazole Impurity H, Pharmaceutical Secondary Standard; Certified Reference Material

BP1174

Fluconazole, British Pharmacopoeia (BP) Reference Standard

BP1175

Fluconazole impurity standard, British Pharmacopoeia (BP) Reference Standard

PHR2048

Fluconazole Impurity G, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2046

Fluconazole Impurity E, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1900

Fluconazole Impurity A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR9026

1,2,4-Triazole, reference material

PHR9031

2-(2,4-Difluorophenyl)-1,2,3-propanetriol, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland

Pictograms

Exclamation markHealth hazard
GHS07,GHS08

Signal Word

Danger

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 3 - Lact. - Repr. 1B

Storage Class Code

6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Documents related to the products that you have purchased in the past have been gathered in the Document Library for your convenience.

Visit the Document Library

Difficulty Finding Your Product Or Lot/Batch Number?

Product numbers are combined with Pack Sizes/Quantity when displayed on the website (example: T1503-25G). Please make sure you enter ONLY the product number in the Product Number field (example: T1503).

Example:

T1503
Product Number
-
25G
Pack Size/Quantity

Additional examples:

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

enter as 1.000309185)

Having trouble? Feel free to contact Technical Service for assistance.

Lot and Batch Numbers can be found on a product's label following the words 'Lot' or 'Batch'.

Aldrich Products

  • For a lot number such as TO09019TO, enter it as 09019TO (without the first two letters 'TO').

  • For a lot number with a filling-code such as 05427ES-021, enter it as 05427ES (without the filling-code '-021').

  • For a lot number with a filling-code such as STBB0728K9, enter it as STBB0728 without the filling-code 'K9'.

Not Finding What You Are Looking For?

In some cases, a COA may not be available online. If your search was unable to find the COA you can request one.

Request COA

A-C L Meyer et al.
Tropical medicine & international health : TM & IH, 18(4), 495-503 (2013-02-02)
To test the hypothesis that a screening and treatment intervention for early cryptococcal infection would improve survival among HIV-infected individuals with low CD4 cell counts. Newly enrolled patients at Family AIDS Care and Education Services (FACES) in Kenya with CD4 ≤ 100
Marcio Nucci et al.
PloS one, 8(3), e59373-e59373 (2013-03-26)
The epidemiology of candidemia varies depending on the geographic region. Little is known about the epidemiology of candidemia in Latin America. We conducted a 24-month laboratory-based survey of candidemia in 20 centers of seven Latin American countries. Incidence rates were
Nicholas G Wysham et al.
Chest, 143(5), 1478-1479 (2013-05-08)
We report a case of Cryptococcus neoformans pneumonia in a patient taking ruxolitinib, a janus kinase 1,2 inhibitor approved for the treatment of myelofibrosis. We hypothesize that ruxolitinib contributed to this infection through its effects on cell-mediated immunity. Clinicians should
Wei Zhao et al.
Clinical pharmacokinetics, 53(11), 1005-1018 (2014-08-27)
Selection of the first-dose-in-neonates is challenging. The objective of this proof-of-concept study was to evaluate a pharmacokinetic bridging approach to predict a neonatal dosing regimen. We selected fluconazole as a paradigm compound. We used data from studies in juvenile mice
Jana Bogum et al.
Journal of the American Society of Nephrology : JASN, 24(5), 744-758 (2013-04-06)
In the principal cells of the renal collecting duct, arginine vasopressin (AVP) stimulates the synthesis of cAMP, leading to signaling events that culminate in the phosphorylation of aquaporin-2 water channels and their redistribution from intracellular domains to the plasma membrane
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service